TSE:GUD - Knight Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started C$7.46 -0.01 (-0.13 %) (As of 05/20/2019 01:28 PM ET)Previous CloseC$7.47Today's RangeC$7.42 - C$7.4752-Week RangeC$7.10 - C$8.81Volume134,200 shsAverage Volume347,584 shsMarket CapitalizationC$1.07 billionP/E Ratio47.52Dividend YieldN/ABetaN/A ProfileAnalyst RatingsChartEarningsInsider TradesHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Knight Therapeutics Inc. operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Impavido, an alkyllysophospholipid analogue drug for visceral and cutaneous Leishmaniasis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; and Flat Tummy Tea, a herbal detox tea. The company also develops Probuphine to treat opioid addiction; NeurAxon family for acute migraine, pain, and neurological disorders; Antibe family to treat chronic pain and inflammation; AzaSite for bacterial conjunctivitis; Iluvien to treat diabetic macular edema; Netildex for ocular inflammation; 60P family to treat tropical diseases; Advaxis family to treat HPV-associated cancers and others; PHOTOFRIN for oesophageal and endobronchial cancer, high-grade dysplasia in Barrett's oesophagus, and papillary bladder cancer; ATryn to prevent thromboembolic events; Ember family to treat osteoarthritis, chronic kidney diseases, alport syndrome, and metabolic diseases; and blood factor products. In addition, it develops FLEXISEQ for pain and joint stiffness associated with osteoarthritis; dermo-cosmetic line of products, such as Crescita family, Laboratoire Dr. Renaud, Premiology, and Pro-Derm; SEQuaderma, an active dermatology solution; HandMD skin care products; and UrgentRx, a fast-acting, portable over-the-counter medication. Further, the company develops TULSA-PRO, a medical device for prostate ablation; and 3D family diagnostic and prognostic products for cancers and neurological disorders. Additionally, it finances other life science companies; and invests in life sciences venture capital funds. The company is headquartered in Montreal, Canada. Receive GUD News and Ratings via Email Sign-up to receive the latest news and ratings for GUD and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange TSE Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolTSE:GUD Previous Symbol CUSIPN/A CIKN/A Webwww.gud-knight.com Phone514-484-4483Debt Debt-to-Equity Ratio0.10 Current Ratio32.29 Quick Ratio32.24Price-To-Earnings Trailing P/E Ratio47.52 Forward P/E Ratio43.88 P/E Growth1556.25 Sales & Book Value Annual SalesC$12.30 million Price / Sales86.63 Cash FlowC$4.46 per share Price / Cash Flow1.67 Book ValueC$7.23 per share Price / Book1.03Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees27 Outstanding Shares142,860,000Market CapC$1.07 billion Next Earnings Date8/8/2019 (Estimated) OptionableNot Optionable Knight Therapeutics (TSE:GUD) Frequently Asked Questions What is Knight Therapeutics' stock symbol? Knight Therapeutics trades on the Toronto Stock Exchange (TSX) under the ticker symbol "GUD." How were Knight Therapeutics' earnings last quarter? Knight Therapeutics Inc (TSE:GUD) posted its earnings results on Thursday, May, 9th. The company reported $0.04 EPS for the quarter, topping the consensus estimate of $0.03 by $0.01. The company had revenue of $2.96 million for the quarter, compared to analyst estimates of $3.06 million. View Knight Therapeutics' Earnings History. When is Knight Therapeutics' next earnings date? Knight Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, August 8th 2019. View Earnings Estimates for Knight Therapeutics. What price target have analysts set for GUD? 2 equities research analysts have issued 12 month price objectives for Knight Therapeutics' shares. Their predictions range from C$10.00 to C$10.25. On average, they anticipate Knight Therapeutics' stock price to reach C$10.13 in the next twelve months. This suggests a possible upside of 35.7% from the stock's current price. View Analyst Price Targets for Knight Therapeutics. What is the consensus analysts' recommendation for Knight Therapeutics? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Knight Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Knight Therapeutics. Has Knight Therapeutics been receiving favorable news coverage? News stories about GUD stock have trended somewhat negative on Monday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Knight Therapeutics earned a news sentiment score of -1.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future. Who are some of Knight Therapeutics' key competitors? Some companies that are related to Knight Therapeutics include Hikma Pharmaceuticals (HIK), Evotec (EVT), Aphria (APHA), Hexo (HEXO), OrganiGram (OGI), HEXO (HEXO), CannTrust (TRST), Green Organic Dutchman (TGOD), Supreme Cannabis (FIRE), Flowr (FLWR), Supreme Cannabis (FIRE), HLS Therapeutics (HLS), HLS Therapeutics (HLS), Benchmark (BMK) and Depomed (ASRT). What other stocks do shareholders of Knight Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Knight Therapeutics investors own include Constellation Software (CSU), Mondi (MNDI), Bombardier, Inc. Class B (BBD.B), Spin Master (TOY), Extendicare (EXE), Allena Pharmaceuticals (ALNA), Franco Nevada (FNV), Exxon Mobil (XOM), Aurora Cannabis (ACB) and Alimentation Couche-Tard (ATD.B). Who are Knight Therapeutics' key executives? Knight Therapeutics' management team includes the folowing people: Mr. Jonathan Ross Goodman BA, LLB, MBA, CEO & Director (Age 50)Ms. Samira Sakhia C.A., C.P.A., M.B.A., MBA, BCom, CPA, DPA, CA, Pres, CFO & Director (Age 50)Mr. Michel Loustric, Pres of Knight BarbadosMs. Amal Khouri, VP of Bus. Devel.Ms. Jody Engel, Director of Bus. Devel. How do I buy shares of Knight Therapeutics? Shares of GUD and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab. What is Knight Therapeutics' stock price today? One share of GUD stock can currently be purchased for approximately C$7.46. How big of a company is Knight Therapeutics? Knight Therapeutics has a market capitalization of C$1.07 billion and generates C$12.30 million in revenue each year. Knight Therapeutics employs 27 workers across the globe. What is Knight Therapeutics' official website? The official website for Knight Therapeutics is http://www.gud-knight.com. How can I contact Knight Therapeutics? The company can be reached via phone at 514-484-4483. MarketBeat Community Rating for Knight Therapeutics (TSE GUD)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 46 (Vote Outperform)Underperform Votes: 37 (Vote Underperform)Total Votes: 83MarketBeat's community ratings are surveys of what our community members think about Knight Therapeutics and other stocks. Vote "Outperform" if you believe GUD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GUD will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/20/2019 by MarketBeat.com StaffFeatured Article: What is the Coverage Ratio? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.